Editorial: Leptin as a therapeutic agent - Trials and tribulations

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 11, 2000, Pages 4000-4002

  Mantzoros, C S ^a   Flier, J S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; EDITORIAL; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH CARE; HUMAN; MALE; MORTALITY; MOUSE; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; UNITED STATES;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CLINICAL TRIALS; HUMANS; LACTONES; LEPTIN; OBESITY; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0034520485     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.11.4000     Document Type: Editorial

References (12)

1. The disease burden associated with overweight and obesity
2. Annual deaths attributable to obesity in the United States
3. Leptin and the regulation of body weight in mammals
4. The role of leptin in human obesity and disease: A review of current evidence
5. Leptin regulation of neuroendocrine systems
6. CSF leptin levels after exogenous administration of recombinant methionyl human leptin
7. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men
8. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
9. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
10. Significant body composition changes observed in obese subjects receiving chronic subcutaneous administration of a modified form of recombinant human leptin
11. Medicinal strategies in the treatment of obesity
12. Role of leptin in the neuroendocrine response to fasting